Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Tai Wang, PhD

Research Fellow

Lab Phone

+1 (646) 888-2216


Tai Wang is a Research Fellow who has a wide range of expertise covering subjects in Biology, Chemistry (Computational), Pharmacology and Bioinformatics. He received his undergraduate and graduate education in Biochemistry in France and Switzerland, respectively. During his PhD studies, he acquired strong skills in Computational Biology and Computational Chemistry through a drug discovery project for species-selective inhibitors of HSP90 using computer-aided drug design and molecular dynamics simulations. 

Since joining Dr. Chiosis’ lab in February 2015, he continued to foster his skills in Computational Biology. His interdisciplinary expertise put him in a unique position to work as a data scientist who devises analytical algorithms and visualization methods for complex “big biological data” generated in the lab. He independently developed a series of R programs that enabled the analyses of large proteomic datasets. These were key for deriving several mechanistic hypotheses related to tumor mechanisms and the role of chaperones in diseases. 

Besides computational studies, he is building on his previous wet-bench skills with new experiences in Pharmacology and Translational Science in Dr. Chiosis’ lab. He focuses on the study of stress chaperome complexes (“epichaperomes”) and their pathologic relevance in a variety of diseases, such as in cancers and neurodegenerative diseases, using biochemical methods and computer models. He works to develop biochemical methods for the precise analysis of chaperome complexes in native tumors and in tumors in which these complexes are modulated upon chemotherapy induced cellular stress. He is implementing these methods into his current project (funded by a postdoctoral award from the Lymphoma Research Foundation), which aims to develop novel rational combination regimens for aggressive lymphomas.


  1. Rodina A*, Wang T*, Yan P*, Gomes ED*, Dunphy MP*, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, Larson SM, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature 2016 Oct 20;538(7625):397-401.  *co-1st authors

  2. Wang T, Guzman ML, Chiosis G. The epichaperome: the power of many as the power of one. Oncoscience 2016 Oct 26;3(9-10):266-267.

  3. Wang T, Mäser P, Picard D, Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles. J. Med. Chem. 2016 Jul 14;59(13):6344-52.

  4. Inda C, Bolaender A, Wang T, Gandu SR, Koren III J. Stressing Out Hsp90 in Neurotoxic Proteinopathies. Curr.Top. Med. Chem. 2016 Apr 13. 16(25):2829-38.

  5. Wang T, Bisson, WH, Mäser P, Scapozza L, Picard D. Differences in conformational dynamics between Plasmodium falciparum and human Hsp90 orthologs enable the structure-based discovery of pathogen-selective inhibitors. J. Med. Chem. 2014; 57(6):2524-2535.

  6.  Wang T., Echeverría PC., Picard D. Overview of molecular chaperones in human health and diseases.  In: Machajewski TD, Gao Z, eds. Inhibitors of Molecular Chaperones as Therapeutic Agents. Cambridge: RSC Publishing, 2014:1-36.